Tirzepatide
A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). Shows superior weight loss efficacy vs. semaglutide in trials.
Peptide
What it is
Detailed description coming soon.
Found in these substances
★
Effects & Mechanisms
Effects profile coming soon — content generated via CMS.
What the Research Says
Research summary coming soon.
Sources & Citations
Sources will appear here once content is generated via the CMS.